Opinion
Video
Author(s):
Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.
Video content above is prompted by the following:
CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer
Korean Study Finds DOAC Use “Seems Effective” in Patients With MPNs